CAMBRIDGE, Mass.--()--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced presentations at two upcoming scientific conferences:
“We look forward to sharing with scientific and medical experts the progress we have made with our proprietary Medicinal Nanoengineering® platform which has led to the development of a pipeline of Accurins, including our lead product, BIND-014, currently entering Phase 2 clinical studies in oncology.”
Nanomedicines Alliance Industry Symposium,
March 6-7, 2013, Rockville, MD
- BIND will provide an oral presentation entitled “Managing Scale-up Challenges for Nanomedicines” in a session discussing Nanomedicine Chemistry Manufacturing and Controls.
Nanotech Conference 2013, May 12-16,
2013, Washington, DC
- BIND will provide an oral presentation entitled “Accurins: Next Generation Targeted Cancer Therapeutics” in a session discussing Cancer Nanotechnology.
“BIND is recognized as a leader in the design and optimization of targeted therapeutics with precisely controlled physicochemical and pharmacological properties,” said Jeff Hrkach, Ph.D. Sr. Vice President, Technology, Research and Development of BIND. “We look forward to sharing with scientific and medical experts the progress we have made with our proprietary Medicinal Nanoengineering® platform which has led to the development of a pipeline of Accurins, including our lead product, BIND-014, currently entering Phase 2 clinical studies in oncology.”
BIND Biosciences is discovering and developing Accurins, proprietary new best-in-class therapeutics with superior target selectivity and the potential to improve patient outcomes. Leveraging its proprietary Medicinal Nanoengineering® platform, BIND develops Accurins that outperform conventional drugs by selectively accumulating in diseased tissues and cells. The result is higher drug concentrations at the site of action with minimal off-target exposure, leading to markedly better efficacy and safety.
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Medicinal NanoengineeringTM platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, dramatically enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes. BIND's lead product candidate, BIND-014, is currently entering Phase 2 clinical testing in cancer patients and is designed to selectively target a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.